T. Rowe Price Associates
MNPR icon

T. Rowe Price Associates’s Monopar Therapeutics MNPR Stock Holding History

T. Rowe Price Associates’s Portfolio MNPR Stock Details MNPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$343K Sell
3,699
-44,003
-92% -$2.72M ﹤0.01% 2797
2026
Q1 		$2.61M Buy
47,702
+24,975
+110% +$1.51M ﹤0.01% 1709
2025
Q4 		$1.49M Buy
+22,727
New +$1.86M ﹤0.01% 1899

Other funds holding MNPR

JT
Jupiter Topco New York $245B AUM
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

T. Rowe Price Associates's MNPR Position: Q2 2026 in Review

T. Rowe Price Associates reduced its Monopar Therapeutics (MNPR) stake by 92% in Q2 2026, selling an estimated $2.72M and leaving 3,699 shares worth $343K. The position accounts for ﹤0.01% of the portfolio, ranked #2797.

T. Rowe Price Associates first reported a position in MNPR in Q4 2025 and has held it in 3 quarters since. The position peaked at $2.61M in Q1 2026. 95 funds tracked by Wall St. Rank hold MNPR as of Q2 2026.

  • T. Rowe Price Associates held 3,699 shares of Monopar Therapeutics worth $343K as of Q2 2026.
  • T. Rowe Price Associates sold 44,003 Monopar Therapeutics shares in Q2 2026, an estimated $2.72M.
  • Monopar Therapeutics made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #2797 holding.
  • T. Rowe Price Associates first reported a position in Monopar Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • T. Rowe Price Associates's Monopar Therapeutics position peaked at $2.61M in Q1 2026.
  • 95 funds tracked by Wall St. Rank held Monopar Therapeutics as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.